One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine Is Immunogenic in 9- to 12-Month-Old Children

Klein, Nicola P.; Baine, Yaela; Bianco, Véronique; Lestrate, Pascal; Naz, Aftab; Blatter, Mark M.; Friedland, Leonard R.; Miller, Jacqueline M.

doi:10.1097/inf.0b013e31828693c5

Cited by 37 publications

(55 citation statements)

References 27 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, waning of antibody titers against serogroup C over time is a well-known phenomenon across age groups. 30,31 Persistence of antibodies against serogroup A was the lowest across serogroups, consistent with trends seen across studies (Fig. 4).…”

Section: Persistence After Multi-dose Vaccination Series In Infants Asupporting

confidence: 68%

Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants

Baxter

Keshavan

Welsch

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Persistence of bactericidal antibodies following vaccination is extremely important for protection against invasive meningococcal disease, given the epidemiology and rapid progression of meningococcal infection. We present an analysis of antibody persistence and booster response to MenACWY-CRM, in adolescents, children and infants, from 7 clinical studies. Immunogenicity was assessed using the serum bactericidal assay with both human and rabbit complement. Post-vaccination hSBA titers were high, with an age-and serogroup-specific decline in titers up to 1 y and stable levels up to 5 y The waning of hSBA titers over time was more pronounced among infants and toddlers and the greatest for serogroup A. However, rSBA titers against serogroup A were consistently higher and showed little decline over time, suggesting that protection against this serogroup may be sustained. A single booster dose of MenACWY-CRM administered at 3 to 5 y induced a robust immune response in all age groups.

show abstract

Section: Persistence After Multi-dose Vaccination Series In Infants Asupporting

confidence: 68%

Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants

Baxter

Keshavan

Welsch

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…The rapid decline in hSBA titers following a single dose has been observed with other group A meningococcal conjugate vaccines (16)(17)(18)(19)(20) and is consistent with observations reported in this population for rSBA GMT and IgG GMC. However, the magnitude of hSBA response is much less, and by threshold analyses, hSBA persists in a smaller proportion of the immunized group than indicated by rSBA or IgG ELISA immunoassays (2).…”

Section: Discussionsupporting

confidence: 78%

Development and Use of a Serum Bactericidal Assay Using Pooled Human Complement To Assess Responses to a Meningococcal Group A Conjugate Vaccine in African Toddlers

Bash

Lynn

Mocca

et al. 2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

A meningococcal group A polysaccharide (PS) conjugate vaccine (PsA-TT) has been developed for African countries affected by epidemic meningitis caused by Neisseria meningitidis. Complement-mediated serum bactericidal antibody (SBA) assays are used to assess protective immune responses to meningococcal vaccination. Human complement (hC=) was used in early studies demonstrating antibody-mediated protection against disease, but it is difficult to obtain and standardize. We developed and evaluated a method for sourcing hC= and then used the SBA assay with hC= (hSBA) to measure bactericidal responses to PsA-TT vaccination in 12-to 23-month-old African children. Sera with active complement from 100 unvaccinated blood donors were tested for intrinsic bactericidal activity, SBA titer using rabbit complement (rSBA), and anti-group A PS antibody concentration. Performance criteria and pooling strategies were examined and then verified by comparisons of three independently prepared hC= lots in two laboratories. hSBA titers of clinical trial sera were then determined using this complement sourcing method. Two different functional antibody tests were necessary for screening hC=. hSBA titers determined using three independent lots of pooled hC= were within expected assay variation among lots and between laboratories. In African toddlers, PsA-TT elicited higher hSBA titers than meningococcal polysaccharide or Hib vaccines. PsA-TT immunization or PS challenge of PsA-TTprimed subjects resulted in vigorous hSBA memory responses, and titers persisted in boosted groups for over a year. Quantifying SBA using pooled hC= is feasible and showed that PsA-TT was highly immunogenic in African toddlers.

show abstract

“…Klein ve ark. (24) 12. ayda tek doz ile 9 ve 12. aylarda 2 doz aşı uygulamasını karşılaştırmışlar ve her iki grupta da A dışın-daki diğer serotipler için bir yıl sonraki rSBA düzeyi-nin korunduğunu bildirmişlerdir.…”

Section: Menacwy-tt Ile Ilgili Yürütülen Antikor Sürekliliğiunclassified

“…'nın (28) çalışmalarında MenACWY-TT ile MenC-CRM197 (Meningitec TM , Wyeth) ve PS aşıları (Mencevax TM ) karşılaştırılmış ve aşıların genel olarak iyi tolere edildiği, özellikle 12-14 ay ve 3-5 yaş arası grupta 3. derece olarak belirtilen yan etki insidansının her grup için düşük olduğu ve bu yaş grubunda en sık saptanan lokal yan etkinin aşı yerinde kızarıklık gelişimi olduğu ifade edilmiştir. Dokuzuncu ayda aşılanan çocukların incelendiği diğer bir çalışmada, %3.3 oranında ateş göz-lenmiş olup, hiçbir vakada >40°C'nin üzerine çıkma-dığı raporlanmıştır (24) . MenACWY-TT ve MenC-CRM aşılarının etkinliğinin 12-24 ay arası çocuklar-da karşılaştırıldığı diğer bir çalışmada, yan etki insidansı benzer bulunmuş olup, enjeksiyon yerinde kızarıklık ve huzursuzluk en sık bildirilen lokal ve sistemik istenmeyen etkiler olmuştur (23) .…”

Section: Menacwy-tt Ile Ilgili Yürütülen Antikor Sürekliliğiunclassified

Meningococcal Vaccines

Somer¹,

Acar²

2017

Cocuk Dergisi

View full text Add to dashboard Cite

show abstract

One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine Is Immunogenic in 9- to 12-Month-Old Children

Cited by 37 publications

References 27 publications

Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants

Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants

Development and Use of a Serum Bactericidal Assay Using Pooled Human Complement To Assess Responses to a Meningococcal Group A Conjugate Vaccine in African Toddlers

Meningococcal Vaccines

Contact Info

Product

Resources

About